India will participate in the World Health Organisation's (WHO) multi-country 'solidarity trial' for developing potential treatments and drugs for COVID-19, the Indian Council of Medical Research (ICMR) said on Friday.
"ICMR will collaborate with WHO for public health emergency 'Solidarity Trial' -- an international randomised trial of additional treatments for COVID-19 in hospitalised patients," ICMR said.
It will be coordinated in India by Dr Sheela Godbole, Scientist, ICMR-National AIDS Research Institute in Pune.
Earlier on March 27, Dr R Ganga Ketkar of ICMR said that India was likely to participate in the WHO's 'solidarity trial' for a potential treatment for COVID-19.
Addressing a press conference, he had said, "We are likely to start our participation soon in the solidarity trial that the WHO is starting."
Coronavirus continued to rise on Friday with India's tally climbing to 2,547, including 162 cured or discharged and 62 deaths, according to the Union Ministry of Health and Family Welfare.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app